KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old targetMarta Román, Ignacio Gil‐Bazo, Inés López et al.|Molecular Cancer|2018Cited by 306
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancerAdrián Vallejo, Silvestre Vicent|Nature Communications|2017Cited by 194
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreasKarmele Valencia, Silvestre Vicent|Journal of Clinical Investigation|2019Cited by 50
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancerRodrigo Entrialgo‐Cadierno, Silvestre Vicent|Molecular Cancer|2023Cited by 24
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancerIrati Macaya, Silvestre Vicent|Nature Communications|2023Cited by 23